Does Rallies show Form 4 insider transactions for NGNE?

Yes. Rallies tracks NGNE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NGNE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NGNE. It does not provide personalized investment advice.

NGNE (Neurogene, Inc. Common Stock) Stock Analysis - Insider Trades

Neurogene, Inc. Common Stock (NGNE) is a publicly traded Healthcare sector company. As of May 21, 2026, NGNE trades at $26.95 with a market cap of $442.14M and a P/E ratio of -6.31. NGNE moved +0.28% today. Year to date, NGNE is +46.23%; over the trailing twelve months it is +45.28%. Its 52-week range spans $6.88 to $74.49. Analyst consensus is strong buy with an average price target of $81.67. Rallies surfaces NGNE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NGNE stock inside the company?

Recent NGNE insider activity includes Cvijic Christine Mikail sold 4.80K, Cvijic Christine Mikail sold 4.80K, Cvijic Christine Mikail sold 2.56K, McMinn Rachel sold 3.35K, and Jordan Julie sold 828. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NGNE Key Metrics

Key financial metrics for NGNE
Metric	Value
Price	$26.95
Market Cap	$442.14M
P/E Ratio	-6.31
EPS	$-4.24
Dividend Yield	0.00%
52-Week High	$74.49
52-Week Low	$6.88
Volume	145.97K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-90.35M
Gross Margin	0.00%

Recent NGNE Insider Trades

Cvijic Christine Mikail sold 4.80K (~$144.35K) on May 6, 2026.
Cvijic Christine Mikail sold 4.80K (~$155.69K) on May 6, 2026.
Cvijic Christine Mikail sold 2.56K (~$55.32K) on Mar 26, 2026.
McMinn Rachel sold 3.35K (~$74.00K) on Mar 26, 2026.
Jordan Julie sold 828 (~$18.13K) on Mar 26, 2026.

Latest NGNE News

Neurogene to Present ICV NGN-401 Data Showing Superior Brain Biodistribution — Apr 28, 2026
Neurogene Secures FDA Breakthrough Designation for Rett Therapy After Phase 1/2 Data — Feb 27, 2026
Neurogene Plans Mid-2026 NGN-401 Update After Q4 2025 Pivotal Dosing — Feb 14, 2026

NGNE Analyst Consensus

8 analysts cover NGNE: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $81.67.

Common questions about NGNE

Who is trading NGNE stock inside the company?: Recent NGNE insider activity includes Cvijic Christine Mikail sold 4.80K, Cvijic Christine Mikail sold 4.80K, Cvijic Christine Mikail sold 2.56K, McMinn Rachel sold 3.35K, and Jordan Julie sold 828. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NGNE?: Yes. Rallies tracks NGNE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NGNE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NGNE. It does not provide personalized investment advice.